Latest News

(UroToday.com) Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 trial […]

(UroToday.com) Tivozanib is a potent and highly selective VEGF receptor tyrosine kinase inhibitor in clinical development for renal cell carcinoma (RCC). Axitinib is also a potent and selective VEGF-receptor inhibitor now commonly part of front-line advanced RCC treatment. In the TIVO-3 trial, tivozanib demonstrated significantly greater progression-free survival (PFS) (hazard ratio [HR] 0.73, 95% confidence interval […]

(UroToday.com) Venous tumor thrombus extension occurs in 4-15% cases of renal cell cancer (RCC). The Mayo classification distinguishes four levels of venous tumor thrombus extension between the renal vein and supradiaphragmatic inferior vena cava. Although surgery is performed with curative intent, mortality is high (5-15%) with complications increasing with the level of the venous tumor thrombus. […]

(UroToday.com) Sarcomatoid renal cell carcinoma (RCC) is a well-described histologic entity often featuring rapid progression and aggressive clinical course when compared with classic clear cell RCC. However, there is a paucity of data assessing the genetic alteration landscape of sarcomatoid RCC. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Gennady […]

(UroToday.com) Temporal and spatial heterogeneity have been consistently identified as contributing to perceived discordance between circulating tumor DNA and tissue-based assays. At the 2020 European Society of Medical Oncology Annual Congress, Zengin et al. previously demonstrated the feasibility of circulating tumor DNA assessment in metastatic renal cell carcinoma (mRCC) and preliminarily showed agreement between circulating tumor […]

(UroToday.com) MiT family translocation renal cell carcinomas represent a rare (1-5%) and aggressive subgroup of renal cell carcinoma (RCC) harboring high expression of c-MET. Additionally, these tumors are characterized by chromosomal translocations involving TFE3 and TFEB transcription factor genes. Currently, there are no standard treatments for these patients according to the National Comprehensive Cancer Network (NCCN) […]

Laser therapy has recently been proposed as a novel treatment for stress urinary incontinence (SUI) due to offering several advantages. This study aimed to evaluate the safety and efficacy of laser treatment of SUI by a meta-analysis.

To evaluate the outcomes of excision and primary anastomosis (EPA) for radiation-associated bulbomembranous stenoses using a multi-institutional analysis. The treatment of radiation-associated urethral stenosis is typically complex owing to the adverse impact of radiation on adjacent tissue.

Vaginal LASER therapy is increasingly used in the field of urogynecology, but several points remain unclear. Our goal was to produce a systematic review of available evidence and provide a critical appraisal of available data.

Stress urinary incontinence (SUI) is common after radical prostatectomy and likely to persist despite conservative treatment. The sling is an emerging operation for persistent SUI, but randomised controlled trial (RCT) comparison with the established artificial urinary sphincter (AUS) is lacking.